within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BF04_ArtesunateSulfaleneAndPyrimetham;

model ArtesunateSulfaleneAndPyrimetham
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 2.3333333333333332e-05,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.0015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011666666666666665,
    Tlag = 10.200000000000001);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>ArtesunateSulfaleneAndPyrimethamine</td></tr><tr><td>ATC code:</td><td>P01BF04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose antimalarial combination used in the treatment of uncomplicated Plasmodium falciparum malaria. Artesunate is a fast-acting artemisinin derivative; sulfalene is a long-acting sulfonamide; pyrimethamine is a dihydrofolate reductase inhibitor. This combination is approved and used in some malaria-endemic regions.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic model specifically for the fixed-dose combination of artesunate, sulfalene, and pyrimethamine with ATC P01BF04. Parameter estimates are approximated from component data (adults, oral administration, healthy or malaria-infected subjects).</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P01BF04 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end ArtesunateSulfaleneAndPyrimetham;
